Search Results

U.S. Research Team Discovers Strong Ultrafast Optical Response Induced by Ionizing Radiation, Potentially Advancing Medical Imaging and Sensing Technologies

September 3 news, Stanford University and the U.S. Department of Energy's SLAC National Accelerator Laboratory research team used ultrafast electron and laser pulses to observe a strong ultrafast optical response triggered by ionization processes in semiconductor materials. The related research has been published in Nature Photonics. The researchers believe this discovery could provide new insights for radiography and sensing technologies, and also offer experimental evidence for understanding the fundamental behavior of materials under high-energy particle interactions. Radiation detection is a key technology in particle accelerators, scientific instruments, medical imaging, and security screening equipment. Existing detectors typically face a trade-off between signal strength and response speed: processes with stronger signals tend to be slower, while those with faster response may produce weaker signals...

2026-09-08

South Korea's DuChemBio to Build Country's First Radiopharmaceutical CDMO Plant

South Korean radiopharmaceutical therapy company DuChemBio will build the country's first contract development and manufacturing organization (CDMO) plant dedicated to radiopharmaceuticals, in response to growing demand for radiopharmaceuticals used in the diagnosis and treatment of cancer and neurological diseases. DuChemBio is a subsidiary of healthcare distributor Geo-Young Group. The company recently signed an investment agreement with North Jeolla Province and the city of Jeongeup to invest KRW 34.3 billion (approximately USD 25.5 million) in building a new plant in Jeongeup. The company stated that this is the largest investment since Geo-Young acquired DuChemBio. According to the plan, the new facility will integrate radioisotope production...

2026-09-08

Cancer Hospital of the First Hospital of Jilin University Established, Granted Configuration Permit for Heavy Ion Radiotherapy System

Recently, the 7th Bethune Conference on New Advances in Cancer Treatment was held in Changchun, Jilin Province. The conference coincided with the 80th anniversary of Jilin University and the 20th anniversary of the Cancer Center of the First Hospital of Jilin University, aiming to establish a high-level academic exchange platform and promote the continuous improvement of cancer diagnosis and treatment capabilities in the three northeastern provinces. During the conference, the inauguration ceremony of the Cancer Hospital of the First Hospital of Jilin University was also held. According to reports, the newly established Cancer Hospital will, based on the coordinated development of the original Cancer Center, integrate three advantageous disciplines—oncology, hematology, and radiation oncology—further improve the multidisciplinary collaborative diagnosis and treatment model, promote smoother connections in cancer diagnosis and treatment processes, and enhance comprehensive treatment capabilities for difficult cancers. The conference also...

2026-09-08

Japanese Research Uses Tau PET to Reveal Association with Symptom Progression in Progressive Supranuclear Palsy

A research team at the National Institutes for Quantum Science and Technology (QST) in Japan recently announced findings from a study on progressive supranuclear palsy (PSP). Using their self-developed tau PET imaging technology, the researchers conducted follow-up scans on the same group of PSP patients at approximately one-year intervals, confirming for the first time in living brains that the faster tau protein accumulates in the globus pallidus region deep within the brain, the faster patient symptoms progress. The findings were published on September 5, 2026, in the international neurology journal *Movement Disorders*. Characteristic tau protein accumulation regions in PSP Progressive supranuclear palsy is a progressive neurodegenerative disease occurring in middle-aged and older adults, with common manifestations including increased risk of falls, difficulty with movement, eye movement disorders, postural instability, and cognitive dysfunction. There is currently no therapy that can cure or halt disease progression; therefore, establishing biomarkers that can objectively reflect disease changes and treatment efficacy has been a critical issue in drug development. Previous autopsy studies have shown that abnormal tau protein accumulation in the brains of PSP patients is an important pathological feature, particularly concentrated in deep brain regions such as the globus pallidus and midbrain. However, autopsy samples cannot be used for long-term dynamic observation, and how tau protein accumulation changes over time and how it corresponds to symptom progression had previously remained unclear. In recent years, positron emission tomography (PET) has made it possible to observe tau protein in living brains, but existing studies have mainly shown that tau protein increases over time without sufficiently demonstrating a direct association between these changes and symptom worsening. In this study, the research team used the PET radiopharmaceutical 18F-PM-PBB3 developed by QST, namely florzolotau (18F), to perform two PET examinations on 26 PSP patients and 10 healthy controls, conducted at baseline and approximately one year later. The researchers combined 57 brain regions identified by MRI and performed multivariate analysis of PET signal changes to identify PSP-related tau protein accumulation regions and their spread over time. The results showed that at baseline, tau protein in PSP patients was primarily accumulated in subcortical regions such as the globus pallidus and midbrain, consistent with previous reports. Follow-up imaging at one year showed further increases in tau protein accumulation in the globus pallidus, along with marked increases in tau accumulation in the frontoparietal lobes and cerebellar white matter, suggesting that during the course of PSP, tau protein may spread from deep brain regions to the cerebral cortex and cerebellar-related areas. The research team further focused on Richardson's syndrome, the most typical and common subtype of PSP. This subtype typically progresses rapidly, and the 18 patients with this subtype included in this study showed significant increases in PSP rating scale scores within one year. The analysis found that changes in tau protein accumulation in the globus pallidus showed the strongest correlation with the degree of symptom progression; that is, the faster tau protein accumulated in this region, the more pronounced the worsening of patient symptoms. Analyses of individual patients likewise showed that globus pallidus tau protein accumulation can reflect the course of PSP from mild to severe stages. The researchers believe that serial tau PET imaging has the potential to serve as a novel imaging biomarker for assessing PSP disease progression, and also provides a basis for tau-targeted therapeutic strategies: if future therapies can inhibit tau protein accumulation, it may be possible to slow symptom progression. Next steps still require longer-term follow-up in a larger number of patients to validate the relationship between changes in tau protein accumulation and overall symptom progression and treatment response. The imaging assessment method established in this study may not only be used for disease monitoring and clinical trial efficacy evaluation in PSP, but may also be extended to research on other tau protein-related neurodegenerative diseases and dementias, providing new technical support for the diagnosis and therapeutic development of related diseases.

2026-09-07

Russia masters production technology of ultra-pure germanium for gamma detectors

The Giredmet Research Institute, part of Rosatom, recently announced that its researchers have developed technology for producing high-purity germanium (HPGe) for gamma-ray detectors. This breakthrough is expected to replace imported crystals and promote the formation of a complete production cycle for detector equipment within Russia. According to reports, experts at Giredmet have designed and manufactured experimental equipment, and based on this, developed a process for preparing ultra-high-purity germanium single crystals. The purity of the germanium material reaches at least 7N, i.e., 99.99999%, equivalent to only one impurity atom per 10 million atoms of the primary material. The institute stated that the first batch of experimental samples has been obtained, verifying the effectiveness of the adopted deep germanium purification method in achieving the purity level required for detector applications.

2026-09-07

Russian Researchers Propose New Method for Preparing Iron-59 Magnetite Nanoparticles, Potentially Advancing Nuclear Medicine Diagnostics and Therapy

Russian researchers have developed a new method for preparing iron-59-labeled magnetite nanoparticles, which is expected to provide a new material preparation pathway for medical applications such as magnetic resonance imaging, single-photon emission computed tomography, and radionuclide therapy. According to reports, researchers from the Vernadsky Institute of Geochemistry and Analytical Chemistry and the Karpov Institute of Physical Chemistry, both under the Russian Academy of Sciences, have proposed synthesizing iron-59 magnetite nanoparticles using the sol-gel method. The relevant findings have been published in the journal Applied Radiation and Isotopes. The sol-gel method is a chemical approach for preparing nanomaterials, with the core process involving the conversion of a liquid colloidal solution into a gel-like network...

2026-09-07

Atom High-Tech Signs Memorandum of Cooperation with Cambodia's Calmette Hospital and Others to Advance Nuclear Medicine Capacity Building

On September 4, Atom High-Tech, Cambodia's Calmette Hospital, and FFS Company held a trilateral memorandum of cooperation signing ceremony in Beijing. Huo Yingying, Deputy Secretary of the Party Committee of China Isotope & Radiation Corporation (CIRC), attended and delivered a speech, while Zhang Yiming, Secretary of the Party Committee and Chairman of Atom High-Tech, signed on behalf of the company. Established in 1950, Calmette Hospital is one of Cambodia's largest and most technologically advanced public hospitals and serves as a national referral center. It undertakes three core missions: delivering high-quality medical services, training health professionals, and conducting medical research. Currently, the hospital is actively advancing its nuclear medicine capacity by establishing the country's first nuclear medicine department, further improving its oncology diagnosis and treatment and molecular imaging service systems...

2026-09-07

Baiyunshan Xike Visits Jiujiang, Jiangxi to Explore Nuclear Medicine Industry Chain Cooperation

Recently, a delegation from Guangzhou Baiyunshan Xike Health Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Holdings Limited (GP Corp.), visited Jiujiang City, Jiangxi Province, conducting field inspections and discussion exchanges in Ruichang City, Jiujiang Economic Development Zone, and Pengze County, focusing on cooperation across the full nuclear medicine industry chain. Liu Hong, Director of the Scientific Research Project Management Department of GP Corp. and Chairman and General Manager of Baiyunshan Xike, led the core team in exchanges with Chen Shuilian, Member of the Party Leadership Group and Vice Mayor of Jiujiang Municipal People's Government, as well as responsible officials from Ruichang City, Pengze County, and Jiujiang Economic Development Zone, reaching multiple consensuses on subsequent cooperation. The inspection covered key facilities including the Ruichang Institute of Nuclear Physics Applications, the Biomedical (Nuclear) Industrial Park in Jiujiang Economic Development Zone, and the Jiangxi Tianhong Nuclear Technology project site in Pengze County. The delegation conducted in-depth visits to research laboratories, industrial parks, and projects under construction to understand local capabilities in nuclear technology research, isotope R&D infrastructure, project construction progress, as well as land and industrial supporting conditions.

2026-09-07

Canada's AtomVie Opens Large-Scale Radiopharmaceutical R&D and Manufacturing Facility in Hamilton

On September 4, AtomVie Global Radiopharma, a radiopharmaceutical contract development and manufacturing organization, announced the official opening of its new state-of-the-art production facility at 10 Aeropark Boulevard, Hamilton, Ontario, Canada. The facility is designed to support the full-spectrum translation of radiopharmaceuticals from early-stage research and development, through clinical development, to commercial manufacturing. According to reports, the new facility represents an investment of over $160 million and spans 72,300 square feet, making it one of the largest single-site radiopharmaceutical R&D CDMO facilities in North America. The facility offers production capabilities ranging from low-throughput to high-throughput, increasing AtomVie's overall production capacity by more than tenfold, with dedicated spaces configurable to meet clients' subsequent R&D and commercialization needs.

2026-09-05

Radionuclide Ward Officially Launched at Xuguan Campus of Suzhou Nuclear Industry General Hospital under CNNC Medical

On September 3, the radionuclide ward of the Nuclear Medicine Department at the Xuguan Campus of Suzhou Nuclear Industry General Hospital, affiliated with CNNC Medical, was officially inaugurated and put into operation. The ward addresses the standardized radionuclide therapy needs of patients with tumors, thyroid diseases, and endocrine disorders, providing inpatient treatment services with isolation and protection conditions. According to reports, the newly launched radionuclide ward is equipped with radiation protection facilities and intelligent monitoring systems, enabling fully enclosed ward management, treatment process monitoring, and multi-level protection. Following the ward's commissioning, the Nuclear Medicine Department will expand from its previous examination-focused service model into a closed-loop service chain integrating radionuclide diagnosis, drug therapy, isolated hospitalization, and research follow-up, enhancing its capacity to manage complex and critically ill patients...

2026-09-05

China's largest single-building oncology nuclear medicine center to be completed and put into operation in Luzhou, Sichuan

On September 2, the "Myriad Weather in Sichuan · Starting Strong for the '15th Five-Year Plan'" Luzhou special press conference was held in Chengdu. The conference disclosed that China's largest single-building oncology nuclear medicine center is about to be completed and put into operation in Luzhou, Sichuan. Construction site of the Oncology Nuclear Medicine Center of the Affiliated Hospital of Southwest Medical University. The center is a key project of Sichuan Province's regional medical centers. The project has a total investment of 310 million yuan, covers an area of approximately 15,000 square meters, and plans more than 160 beds. It will integrate functions including nuclear medicine molecular imaging, nuclear drug R&D and preparation, radionuclide therapy, tumor radiotherapy, and specialized oncology diagnosis and treatment, and will be built into...

2026-09-03

West Physics Acquires U.S. Medical Physics Services Provider RTS, Expanding Nuclear Medicine and Radiation Safety Service Network

West Physics Consulting, LLC, a U.S. provider of medical and health physics consulting services, announced on September 2, 2026, that it has acquired Radiographic Testing Services, Inc. (RTS). Headquartered in Albany, New York, RTS primarily provides medical physics services covering nuclear medicine, diagnostic radiology, radiation oncology, and Certified Radiological Equipment Safety Officer (CRESO)-related services. West Physics stated that this acquisition will integrate the strengths of both companies in customer service, quality management, and technical capabilities. Upon completion of the transaction, the company will add a new office in Albany, New York, and further expand its presence in Albany, New York...

2026-09-03

Sejong City Requests National Support for Proton Cancer Therapy Center Budget

On September 2, 2026, the Democratic Party of Korea and Sejong City held their first budget policy consultation meeting at the Sejong City Government to discuss key agenda items and budget support for the city. At the meeting, Sejong City Mayor Cho Sang-ho requested the Democratic Party's attention to several issues, including securing national funding for the construction of a cancer proton therapy center, improving the general grant system for Sejong City, and promoting the passage of the Special Act on the Administrative Capital within the year. After the closed-door consultation, a relevant spokesperson stated in a briefing that the meeting proposed allocating 300 million KRW each in the next year's national budget for a feasibility study on the construction of the cancer proton therapy center and for the formulation of the basic plan for the National Central Bioresource Center.

2026-09-02

Prostate cancer becomes most common cancer among men in South Korea, Lu-177 PSMA therapy reaches cumulative 200 procedures

Prostate cancer incidence in South Korea has continued to rise, making it the most common cancer among men in the country. Meanwhile, a novel nuclear medicine treatment for metastatic prostate cancer—Lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand therapy—is accumulating more clinical cases. Seoul St. Mary's Hospital Uro-Oncology Center stated on September 1 that since performing South Korea's first Lu-177 PSMA treatment on November 2, 2020, the center had administered a cumulative total of 200 such treatments to 84 patients with metastatic prostate cancer as of the 21st of last month. Metastatic castration-resistant prostate cancer refers to a state in which prostate cancer continues to progress despite androgen suppression therapy. As the disease advances, patients have fewer treatment options and a worse prognosis, making it essential to select appropriate treatment modalities and sequencing based on prior treatment history and physical condition.

2026-09-02

Ionetix begins routine supply of astatine-211 in North America, expanding sources of isotopes for targeted alpha therapy

Ionetix, a U.S. medical isotope producer, recently announced that it has begun routine supply of astatine-211 (At-211) in North America. The company stated that this development expands the supply sources of At-211 and is expected to support its further application in preclinical research and clinical development. Ionetix noted that it believes it is the first non-academic commercial supplier of At-211 in the United States. Ionetix produces At-211 at its facility in Lansing, Michigan, leveraging its proprietary cyclotron technology. The company currently operates a 30 MeV cyclotron equipped with optimized target technology, aiming to support the production of clinical-grade At-211. The company stated that its production ca...

2026-09-02